Latest Revenue Performance News

IODM Limited has triggered a significant increase in its guaranteed minimum monthly revenue from its UK Education segment, reflecting a remarkable 242% growth in July 2025 compared to last year. This milestone boosts the annualised minimum payment to AUD 2.39 million, underscoring the strength of its digital accounts receivable platform.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.

Chorus Limited’s 2024 fibre regulatory report reveals a stable $5.9 billion asset base and revenue close to the maximum allowed, with a $153.5 million wash-up balance carried forward.

The Australian Wealth Advisors Group has deepened its Equity Partnership Scheme with strategic stakes in Oneledger and B2B Invest, setting up royalty revenue streams that align with its expansion in financial services.

oOh!media Limited reports robust revenue growth momentum continuing into 2025, driven by strong contract wins and disciplined cost management. The company expects sustained market share gains in the expanding Out of Home advertising sector.

Deterra Royalties Limited reported a 4% increase in portfolio revenue to AUD 61.9 million for the March 2025 quarter, driven by robust iron ore royalties and record gold margins. The company also marked a major milestone with the Final Investment Decision and full funding secured for Phase 1 of the Thacker Pass Lithium Project, targeting production in 2027.

ImpediMed Limited has locked in a US$15 million growth capital facility with SWK Funding LLC, providing crucial financial flexibility to advance its SOZO Digital Health Platform and commercial ambitions.